The Mechanism of Action of a JAK Inhibitor for AD
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- C-Suite Chats
New FDA Approval for AD
- Updates in Atopic Dermatitis
Anti-OX40 Ligand Antibody Trials
Stephan Weidinger, MD, PhD
- ISDPA Midwest Derm 2024
ISDPA: Dr. Lal on Therapeutic Updates
Karan Lal, DO, MS, FAAD
- Updates in Atopic Dermatitis
Understanding Disparities in AD
Raj Chovatiya, MD, PhD